Payload Information

General Information of This Payload

Payload ID	PAY0PTQYV
Name	Dasatinib
Synonyms	Dasatinib; 302962-49-8; Sprycel; BMS-354825; Dasatinib anhydrous; BMS 354825; Dasatinib (anhydrous); BMS354825; Dasatinib (BMS-354825); dasatinibum; anh. dasatinib; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; anhydrous dasatinib; dasatinib (anh.); Spyrcel; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; Dasatinib [USAN]; BMS Dasatinib; UNII-X78UG0A0RN; X78UG0A0RN; C22H26ClN7O2S; DTXSID4040979; CHEBI:49375; Dasatinib [USAN:INN]; NSC732517; NSC-759877; CHEMBL1421; DTXCID2020979; BMS-354825 HYDRATE; BMS 345825; NSC-732517; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-; NCGC00181129-01; BMS 35482513; Dasatinib (USAN); BMS-354825-03; SPRYCEL (TN); CHEBI:70839; DTXSID50235486; 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-; n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide; SMR002529551; CAS-302962-49-8; NSC 759877; 302962-49-8 pound not863127-77-9; Dasatinib, BMS 354825; 1N1; Kinome_3650; Dasatinib (JAN/INN); DASATINIB [INN]; DASATINIB [MI]; n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; Sprycel (Bristol Meyers); D0E6XR; DASATINIB [WHO-DD]; SCHEMBL8226; Dasatinib,BMS-354825; MLS003915609; MLS004774145; MLS006010904; Dasatinib - BMS-354825; GTPL5678; BDBM13216; cid_3062316; DTXCID50157977; EX-A401; L01XE06; ZBNZXTGUTAYRHI-UHFFFAOYSA-N; 5-Thiazolecarboxamide, monohydrate; BCPP000263; HMS2043N05; HMS3244A05; HMS3244A06; HMS3244B05; HMS3265C19; HMS3265C20; HMS3265D19; HMS3265D20; HMS3654K05; HMS3744C11; Pharmakon1600-01502275; BCP01797; C22-H26-Cl-N7-O2-S; Tox21_112736; MFCD11046566; NSC759877; NSC800087; s1021; AKOS015902363; Tox21_112736_1; BCP9000589; CCG-264779; CS-0100; CS-O-01350; DB01254; GS-6548; NSC-800087; SB17284; NCGC00181129-02; NCGC00181129-03; NCGC00181129-05; NCGC00181129-06; NCGC00181129-07; NCGC00181129-12; NCGC00181129-14; NCGC00181129-22; NCGC00481571-01; (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; AC-22749; BCB03_000715; HY-10181; N-(2-chloro-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]thiazole-5-carboxamide; LS-186641; LS-187028; LS-187773; AM20080877; D5949; FT-0650671; PA-3062316; SW208076-5; EC-000.2122; D-3307; D03658; EN300-123025; AB01273956-01; AB01273956-02; AB01273956_03; AR-270/43507994; BMS-354825, Sprycel, BMS354825, Dasatinib; Q419940; SR-00000000554; Q-101345; SR-00000000554-5; BRD-K49328571-001-05-1; BRD-K49328571-001-07-7; Z1546610486; 5-tiazolcarboxamida, n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-; N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl}amino)-1,3-thiazole-5-carboxamide; N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide; N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate Click to Show/Hide
Target(s)	Breakpoint cluster region protein (BCR)			Target Info
Structure
Structure	3D MOL		2D MOL
Formula	C22H26ClN7O2S
Isosmiles	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
PubChem CID	3062316
InChI	InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
InChIKey	ZBNZXTGUTAYRHI-UHFFFAOYSA-N
IUPAC Name	N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
Pharmaceutical Properties	Molecule Weight	488	Polar area	135
	Complexity	642	xlogp Value	3.6
	Heavy Count	33	Rot Bonds	7
	Hbond acc	9	Hbond Donor	3

The activity data of This Payload

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half Maximal Inhibitory Concentration (IC50)	0.000109	nM	BV-173 cells	Chronic myelogenous leukemia	CVCL_0181
Half Maximal Inhibitory Concentration (IC50)	0.0002656	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004
Half Maximal Inhibitory Concentration (IC50)	0.0008218	nM	BL-70 cells	Burkitt lymphoma	CVCL_1088
Half Maximal Inhibitory Concentration (IC50)	0.001078	nM	EM-2 cells	Chronic myeloid leukemia	CVCL_1196
Half Maximal Inhibitory Concentration (IC50)	0.003207	nM	LAMA-84 cells	Chronic myeloid leukemia	CVCL_0388
Half Maximal Inhibitory Concentration (IC50)	0.009805	nM	MEG-01 cells	Chronic myeloid leukemia	CVCL_0425
Half Maximal Inhibitory Concentration (IC50)	0.01309	nM	EoL-1 cells	Chronic eosinophilic leukemia	CVCL_0258
Half Maximal Effective Concentration (EC50)	0.04	nM	BaF3 cells	Normal	CVCL_0161	[1]
Half Maximal Inhibitory Concentration (IC50)	0.04036	nM	CTV-1 cells	T acute lymphoblastic leukemia	CVCL_1150
Half Maximal Inhibitory Concentration (IC50)	0.069	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[2]
Half Maximal Inhibitory Concentration (IC50)	0.1	nM	KU812 cells	Chronic myeloid leukemia	CVCL_0379	[3]
Half Maximal Inhibitory Concentration (IC50)	0.11	nM	HL-60 cells	Adult acute myeloid leukemia	CVCL_0002	[2]
Half Maximal Inhibitory Concentration (IC50)	0.19	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[4]
Half Maximal Inhibitory Concentration (IC50)	0.2	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[3]
Half Maximal Inhibitory Concentration (IC50)	0.2	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	0.25	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[6]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	<0.3	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[7]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	<0.3	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	<0.3	nM	KU812 cells	Chronic myeloid leukemia	CVCL_0379	[7]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	<0.3	nM	MEG-01 cells	Chronic myeloid leukemia	CVCL_0425	[7]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	0.37	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[8]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	0.4	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[9]
Half Maximal Inhibitory Concentration (IC50)	0.4	nM	ALL-3 cells	B acute lymphoblastic leukemia	CVCL_QW63	[10]
Half Maximal Inhibitory Concentration (IC50)	0.638	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[11]
Half Maximal Inhibitory Concentration (IC50)	0.7	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[12]
Half Maximal Inhibitory Concentration (IC50)	0.7	nM	BaF3 cells	Normal	CVCL_0161	[3]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	0.81	nM	K-562R cells	Leukemia	CVCL_5950	[8]
Half Maximal Inhibitory Concentration (IC50)	0.9	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[13]
Half Maximal Inhibitory Concentration (IC50)	0.9	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[14]
Half Maximal Inhibitory Concentration (IC50)	0.9	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	<1	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[15]
Half Maximal Inhibitory Concentration (IC50)	<1	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[16]
Half Maximal Inhibitory Concentration (IC50)	1	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[17]
Half Maximal Inhibitory Concentration (IC50)	1	nM	Leukemia cells	Leukemia	Undisclosed	[18]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	1	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	1	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Inhibitory Concentration (IC50)	1.3	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	1.9	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	10	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Inhibitory Concentration (IC50)	<100	nM	PANC-1 cells	Pancreatic ductal adenocarcinoma	CVCL_0480	[19]
Half Maximal Inhibitory Concentration (IC50)	>100	nM	U-937 cells	Adult acute monocytic leukemia	CVCL_0007	[20]
Half Maximal Inhibitory Concentration (IC50)	>100	nM	BaF3 cells	Normal	CVCL_0161	[3]
Half Maximal Inhibitory Concentration (IC50)	>1000	nM	Jurkat cells	T acute lymphoblastic leukemia	CVCL_0065	[3]
Half Maximal Inhibitory Concentration (IC50)	>1000	nM	U-937 cells	Adult acute monocytic leukemia	CVCL_0007	[3]
Half Maximal Effective Concentration (EC50)	>1000	nM	BaF3 cells	Normal	CVCL_0161	[1]
Half Maximal Inhibitory Concentration (IC50)	>1000	nM	BaF3 cells	Normal	CVCL_0161	[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	>10000	nM	U-937 cells	Adult acute monocytic leukemia	CVCL_0007	[7]
Half Maximal Inhibitory Concentration (IC50)	10000	nM	HeLa cells	Endocervical adenocarcinoma	CVCL_0030	[21]
Half Maximal Inhibitory Concentration (IC50)	10000	nM	HeLa cells	Endocervical adenocarcinoma	CVCL_0030	[21]
Half Maximal Inhibitory Concentration (IC50)	10000	nM	HeLa cells	Endocervical adenocarcinoma	CVCL_0030	[21]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	>10000	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Effective Concentration (EC50)	>10000	nM	BaF3 cells	Normal	CVCL_0161	[4]
Half Maximal Effective Concentration (EC50)	>10000	nM	BaF3 cells	Normal	CVCL_0161	[4]
Half Maximal Inhibitory Concentration (IC50)	100000	nM	CHO cells	Normal	CVCL_0213	[22]
Half Maximal Inhibitory Concentration (IC50)	10065.6	nM	EHEB cells	Normal	CVCL_1194
Half Maximal Inhibitory Concentration (IC50)	10208204.11	nM	BE-13 cells	T acute lymphoblastic leukemia	CVCL_1081
Half Maximal Inhibitory Concentration (IC50)	10230	nM	U-937 cells	Adult acute monocytic leukemia	CVCL_0007	[23]
Half Maximal Inhibitory Concentration (IC50)	103.8	nM	RL95-2 cells	Endometrial adenosquamous carcinoma	CVCL_0505
Half Maximal Inhibitory Concentration (IC50)	1030.43	nM	A101D cells	Melanoma	CVCL_1057
Half Maximal Inhibitory Concentration (IC50)	104.4	nM	C2C12 cells	Normal	CVCL_0188	[21]
Half Maximal Inhibitory Concentration (IC50)	1044.12	nM	OCUB-M cells	Breast carcinoma	CVCL_1621
Half Maximal Inhibitory Concentration (IC50)	104711.92	nM	K052 cells	Adult acute myeloid leukemia	CVCL_1321
Half Maximal Inhibitory Concentration (IC50)	104750.47	nM	RH-1 cells	Ewing sarcoma	CVCL_1658
Half Maximal Inhibitory Concentration (IC50)	10477.57	nM	HEL cells	Erythroleukemia	CVCL_0001
Half Maximal Inhibitory Concentration (IC50)	105.4	nM	TF-1 cells	Esophageal squamous cell carcinoma	CVCL_1759
Half Maximal Inhibitory Concentration (IC50)	1051.45	nM	ES4 cells	Ewing sarcoma	CVCL_1200
Half Maximal Inhibitory Concentration (IC50)	10793.76	nM	ALL-PO cells	B acute lymphoblastic leukemia	CVCL_1069
Half Maximal Inhibitory Concentration (IC50)	108075.49	nM	SK-MEL-2 cells (MEK inhibitor-resistant)	Melanoma	CVCL_0069
Half Maximal Inhibitory Concentration (IC50)	11.15	nM	SW982 cells	Biphasic synovial sarcoma	CVCL_1734
Half Maximal Inhibitory Concentration (IC50)	11.74	nM	TK-10 cells	Renal carcinoma	CVCL_1773
Half Maximal Inhibitory Concentration (IC50)	110.28	nM	NCI-H1355 cells	Lung adenocarcinoma	CVCL_1464
Half Maximal Inhibitory Concentration (IC50)	110064.99	nM	EW-13 cells	Ewing sarcoma	CVCL_1211
Half Maximal Inhibitory Concentration (IC50)	1110	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[24]
Half Maximal Inhibitory Concentration (IC50)	112	nM	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma	CVCL_0062	[25]
Half Maximal Inhibitory Concentration (IC50)	112.92	nM	SW 962 cells	Vulva lymphoid carcinoma	CVCL_1733
Half Maximal Inhibitory Concentration (IC50)	1120	nM	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma	CVCL_0062	[26]
Half Maximal Inhibitory Concentration (IC50)	112326.41	nM	NCI-H2196 cells	Lung small cell carcinoma	CVCL_1539
Half Maximal Inhibitory Concentration (IC50)	11282.76	nM	TGW cells	Adrenal gland neuroblastoma	CVCL_1771
Half Maximal Inhibitory Concentration (IC50)	113.17	nM	KLE cells	Endometrial adenocarcinoma	CVCL_1329
Half Maximal Inhibitory Concentration (IC50)	114.1	nM	MC116 cells	B-cell non-Hodgkin lymphoma	CVCL_1399
Half Maximal Inhibitory Concentration (IC50)	115281.39	nM	EKVX cells	Non-small cell lung carcinoma	CVCL_1195
Half Maximal Inhibitory Concentration (IC50)	116114.29	nM	NCI-H1650 cells	Lung adenocarcinoma	CVCL_1483
Half Maximal Inhibitory Concentration (IC50)	117561.55	nM	NCI-H1436 cells	Lung small cell carcinoma	CVCL_1471
Half Maximal Inhibitory Concentration (IC50)	118.83	nM	KU812 cells	Chronic myeloid leukemia	CVCL_0379
Half Maximal Inhibitory Concentration (IC50)	118688.33	nM	NCI-H524 cells	Lung small cell carcinoma	CVCL_1568
Half Maximal Inhibitory Concentration (IC50)	118834.29	nM	EW-11 cells	Ewing sarcoma	CVCL_1209
Half Maximal Inhibitory Concentration (IC50)	11900	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[27]
Half Maximal Inhibitory Concentration (IC50)	11950	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[23]
Half Maximal Inhibitory Concentration (IC50)	119852.28	nM	NCI-H1882 cells	Lung small cell carcinoma	CVCL_1504
Half Maximal Inhibitory Concentration (IC50)	12.4	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[28]
Half Maximal Inhibitory Concentration (IC50)	12113.76	nM	BC-3 cells	Primary effusion lymphoma	CVCL_1080
Half Maximal Inhibitory Concentration (IC50)	1212.26	nM	TE-6 cells	Esophageal squamous cell carcinoma	CVCL_1765
Half Maximal Inhibitory Concentration (IC50)	122.13	nM	COLO-829 cells	Cutaneous melanoma	CVCL_1137
Half Maximal Inhibitory Concentration (IC50)	122.83	nM	NTERA-2-cl-D1 cells	Teratocarcinoma	CVCL_3407
Half Maximal Inhibitory Concentration (IC50)	1233.76	nM	D-502MG cells	Glioblastoma	CVCL_1162
Half Maximal Inhibitory Concentration (IC50)	123540.5	nM	NCI-H345 cells	Lung carcinoma	CVCL_1558
Half Maximal Inhibitory Concentration (IC50)	1244.12	nM	KNS-42 cells	Glioblastoma	CVCL_0378
Half Maximal Inhibitory Concentration (IC50)	12444.5	nM	IA-LM cells	Lung large cell carcinoma	CVCL_1302
Half Maximal Inhibitory Concentration (IC50)	124889.83	nM	LB647-SCLC cells	Lung small cell carcinoma	CVCL_1368
Half Maximal Inhibitory Concentration (IC50)	12660	nM	A-549 cells	Lung adenocarcinoma	CVCL_0023	[12]
Half Maximal Inhibitory Concentration (IC50)	127653.17	nM	GR-ST cells	B acute lymphoblastic leukemia	CVCL_1236
Half Maximal Inhibitory Concentration (IC50)	12830	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[29]
Half Maximal Inhibitory Concentration (IC50)	128474.96	nM	TE-441-T cells	Rhabdomyosarcoma	CVCL_1754
Half Maximal Inhibitory Concentration (IC50)	128865.47	nM	COLO-668 cells	Lung small cell carcinoma	CVCL_1128
Half Maximal Inhibitory Concentration (IC50)	12919.84	nM	UACC-257 cells	Melanoma	CVCL_1779
Half Maximal Inhibitory Concentration (IC50)	12928.25	nM	KP-N-YS cells	Adrenal gland neuroblastoma	CVCL_1342
Half Maximal Inhibitory Concentration (IC50)	129379.64	nM	LS-513 cells	Cecum adenocarcinoma	CVCL_1386
Half Maximal Cell Growth Inhibitory Concentration (GI50)	13	nM	SK-N-FI cells	Neuroblastoma	CVCL_1702	[8]
Half Maximal Inhibitory Concentration (IC50)	1305.89	nM	SNU-C2B cells	Cecum adenocarcinoma	CVCL_1710
Half Maximal Inhibitory Concentration (IC50)	130592.66	nM	CESS cells	Adult acute myeloid leukemia	CVCL_0209
Half Maximal Inhibitory Concentration (IC50)	1307.33	nM	NCI-H1838 cells	Lung adenocarcinoma	CVCL_1499
Half Maximal Inhibitory Concentration (IC50)	1308.59	nM	NKM-1 cells	Acute myeloid leukemia	CVCL_1607
Half Maximal Inhibitory Concentration (IC50)	131158.56	nM	MS-1 cells	Lung small cell carcinoma	CVCL_1429
Half Maximal Inhibitory Concentration (IC50)	131210.38	nM	MFM-223 cells	Breast carcinoma	CVCL_1408
Half Maximal Inhibitory Concentration (IC50)	1325	nM	JeKo-1 cells	Mantle cell lymphoma	CVCL_1865	[30]
Half Maximal Inhibitory Concentration (IC50)	1325	nM	SU-DHL-1 cells	Anaplastic large cell lymphoma	CVCL_0538	[30]
Half Maximal Inhibitory Concentration (IC50)	1325	nM	PCL12 cells	B-cell chronic lymphocytic leukemia	CVCL_2H32	[30]
Half Maximal Inhibitory Concentration (IC50)	1325	nM	Maver1 cells	Mantle cell lymphoma	CVCL_1831	[30]
Half Maximal Inhibitory Concentration (IC50)	1325	nM	Ri-1 cells	Diffuse large B-cell lymphoma	CVCL_1885	[30]
Half Maximal Inhibitory Concentration (IC50)	1325	nM	MEC-1 cells	Chronic lymphocytic leukemia	CVCL_1870	[30]
Half Maximal Inhibitory Concentration (IC50)	132712.35	nM	CAL-148 cells	Breast carcinoma	CVCL_1106
Half Maximal Inhibitory Concentration (IC50)	1327436.61	nM	CCRF-CEM cells	T acute lymphoblastic leukemia	CVCL_0207
Half Maximal Inhibitory Concentration (IC50)	134.5	nM	IST-MEL1 cells	Melanoma	CVCL_1308
Half Maximal Inhibitory Concentration (IC50)	134144.42	nM	NCI-H1092 cells	Lung small cell carcinoma	CVCL_1454
Half Maximal Inhibitory Concentration (IC50)	1362.2	nM	GI-1 cells	Gliosarcoma	CVCL_1231
Half Maximal Inhibitory Concentration (IC50)	13749.67	nM	Raji cells	EBV-related Burkitt lymphoma	CVCL_0511
Half Maximal Inhibitory Concentration (IC50)	137543.19	nM	BT474-M1 cells	Invasive breast carcinoma	CVCL_0179
Half Maximal Inhibitory Concentration (IC50)	137547.46	nM	KY821 cells	Acute myelomonocytic leukemia	CVCL_1346
Half Maximal Inhibitory Concentration (IC50)	137887.9	nM	NCI-H209 cells	Lung small cell carcinoma	CVCL_1525
Half Maximal Inhibitory Concentration (IC50)	1380872.74	nM	ST486 cells	Burkitt lymphoma	CVCL_1712
Half Maximal Inhibitory Concentration (IC50)	138167.26	nM	NCI-H23 cells	Lung adenocarcinoma	CVCL_1547
Half Maximal Inhibitory Concentration (IC50)	13855.73	nM	SF539 cells	Gliosarcoma	CVCL_1691
Half Maximal Inhibitory Concentration (IC50)	1398.27	nM	NB5 cells	Neuroblastoma	CVCL_8822
Half Maximal Cell Growth Inhibitory Concentration (GI50)	14	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Inhibitory Concentration (IC50)	14.91	nM	A704 cells	Renal carcinoma	CVCL_1065
Half Maximal Inhibitory Concentration (IC50)	140.32	nM	MLMA cells	Hairy cell leukemia	CVCL_1419
Half Maximal Inhibitory Concentration (IC50)	140.64	nM	LS-123 cells	Colon adenocarcinoma	CVCL_1383
Half Maximal Inhibitory Concentration (IC50)	14002.8	nM	DMS-153 cells	Lung small cell carcinoma	CVCL_1175
Half Maximal Inhibitory Concentration (IC50)	1409.92	nM	CAS-1 cells	Glioblastoma	CVCL_1117
Half Maximal Inhibitory Concentration (IC50)	141.62	nM	LB2518-MEL cells	Melanoma	CVCL_1366
Half Maximal Inhibitory Concentration (IC50)	14300	nM	HEK cells	Endocervical adenocarcinoma	CVCL_M624	[19]
Half Maximal Inhibitory Concentration (IC50)	143708.36	nM	NCI-H1581 cells	Lung large cell carcinoma	CVCL_1479
Half Maximal Inhibitory Concentration (IC50)	144.36	nM	NB69 cells	Neuroblastoma	CVCL_1448
Half Maximal Inhibitory Concentration (IC50)	144723.93	nM	KP-N-RT-BM-1 cells	Adrenal gland neuroblastoma	CVCL_1339
Half Maximal Inhibitory Concentration (IC50)	146345.61	nM	LU-139 cells	Lung small cell carcinoma	CVCL_1390
Half Maximal Inhibitory Concentration (IC50)	146544.19	nM	NCI-H719 cells	Lung small cell carcinoma	CVCL_1582
Half Maximal Inhibitory Concentration (IC50)	147691.55	nM	EW-1 cells	Ewing sarcoma	CVCL_1208
Half Maximal Inhibitory Concentration (IC50)	15	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	15197.88	nM	MN-60 cells	Burkitt lymphoma	CVCL_1421
Half Maximal Inhibitory Concentration (IC50)	154.58	nM	8-MG-BA cells	Glioblastoma	CVCL_1052
Half Maximal Inhibitory Concentration (IC50)	155586.99	nM	KMS-12-PE cells	Multiple myeloma	CVCL_1333
Half Maximal Inhibitory Concentration (IC50)	156611.94	nM	NCI-H128 cells	Lung carcinoma	CVCL_1460
Half Maximal Inhibitory Concentration (IC50)	1567.14	nM	HCE-T cells	Nornal	CVCL_1272
Half Maximal Inhibitory Concentration (IC50)	1579.84	nM	SBC-1 cells	Lung small cell carcinoma	CVCL_1676
Half Maximal Cell Growth Inhibitory Concentration (GI50)	1586	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022	[8]
Half Maximal Inhibitory Concentration (IC50)	159194.7	nM	NCI-H889 cells	Lung small cell carcinoma	CVCL_1598
Half Maximal Inhibitory Concentration (IC50)	159717.4	nM	GDM-1 cells	Acute myeloid leukemia	CVCL_1230
Half Maximal Cell Growth Inhibitory Concentration (GI50)	160	nM	DU145 cells	Prostate carcinoma	CVCL_0105	[31]
Half Maximal Effective Concentration (EC50)	1600	nM	Peripheral blood mononuclear cells	Normal	Undisclosed	[1]
Half Maximal Inhibitory Concentration (IC50)	161441.2	nM	NCI-H187 cells	Lung small cell carcinoma	CVCL_1501
Half Maximal Cell Growth Inhibitory Concentration (GI50)	163	nM	NCI-H226 cells	Pleural epithelioid mesothelioma	CVCL_1544	[8]
Half Maximal Inhibitory Concentration (IC50)	163145.59	nM	EB2 cells	Burkitt lymphoma	CVCL_1186
Half Maximal Inhibitory Concentration (IC50)	164.89	nM	K5 cells	Thyroid gland papillary carcinoma	CVCL_1322
Half Maximal Inhibitory Concentration (IC50)	166.66	nM	KINGS-1 cells	Anaplastic astrocytoma	CVCL_1328
Half Maximal Inhibitory Concentration (IC50)	167063.34	nM	IMR-5 cells	Neuroblastoma	CVCL_1306
Half Maximal Inhibitory Concentration (IC50)	167642.38	nM	THP-1 cells	Childhood acute monocytic leukemia	CVCL_0006
Half Maximal Inhibitory Concentration (IC50)	168128.91	nM	SCC-3 cells	B-cell non-Hodgkin lymphoma	CVCL_1683
Half Maximal Inhibitory Concentration (IC50)	168273.06	nM	HDLM-2 cells	Hodgkin lymphoma	CVCL_0009
Half Maximal Inhibitory Concentration (IC50)	169693.69	nM	JAR cells	Gestational choriocarcinoma	CVCL_0360
Half Maximal Cell Growth Inhibitory Concentration (GI50)	17	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Inhibitory Concentration (IC50)	17	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	17.19	nM	DoHH2 CDX model cells	Diffuse large B-cell lymphoma germinal center B-cell type	CVCL_1179
Half Maximal Effective Concentration (EC50)	173	nM	NCI-H1975 cells	Lung adenocarcinoma	CVCL_1511	[1]
Half Maximal Inhibitory Concentration (IC50)	173292.17	nM	CPC-N cells	Lung small cell carcinoma	CVCL_1146
Half Maximal Inhibitory Concentration (IC50)	1734.66	nM	JIYOYE cells	Burkitts lymhoma	CVCL_1317
Half Maximal Inhibitory Concentration (IC50)	174.04	nM	SF268 cells	Astrocytoma	CVCL_1689
Half Maximal Inhibitory Concentration (IC50)	174254.17	nM	NCI-H716 cells	Cecum adenocarcinoma	CVCL_1581
Half Maximal Inhibitory Concentration (IC50)	17445.45	nM	RPMI-8866 cells	Chronic myelogenous leukemia	CVCL_1668
Half Maximal Inhibitory Concentration (IC50)	176.78	nM	PF-382 cells	T acute lymphoblastic leukemia	CVCL_1641
Half Maximal Inhibitory Concentration (IC50)	176791.84	nM	ES1 cells	Ewing sarcoma	CVCL_1198
Half Maximal Effective Concentration (EC50)	17689	nM	Vero C1008 cells	Normal	CVCL_0574	[32]
Half Maximal Inhibitory Concentration (IC50)	177208.32	nM	L-363 cells	Plasma cell myeloma	CVCL_1357
Half Maximal Inhibitory Concentration (IC50)	1778.28	nM	HEK293 cells	Normal	CVCL_0045	[33]
Half Maximal Inhibitory Concentration (IC50)	178	nM	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma	CVCL_0062	[34]
Half Maximal Inhibitory Concentration (IC50)	178564.52	nM	LAN-6 cells	Neuroblastoma	CVCL_1363
Half Maximal Inhibitory Concentration (IC50)	1791.39	nM	TE-5 cells	Esophageal squamous cell carcinoma	CVCL_1764
Half Maximal Inhibitory Concentration (IC50)	18.3	nM	HEK293 cells	Normal	CVCL_0045	[35]
Half Maximal Inhibitory Concentration (IC50)	18.34	nM	HOP-62 cells	Non-small cell lung carcinoma	CVCL_1285
Half Maximal Inhibitory Concentration (IC50)	18.61	nM	TE-12 cells	Esophageal squamous cell carcinoma	CVCL_1762
Half Maximal Inhibitory Concentration (IC50)	1822.52	nM	ACN cells	Melanoma	CVCL_1068
Half Maximal Inhibitory Concentration (IC50)	184.13	nM	SH-4 cells	Melanoma	CVCL_1692
Half Maximal Inhibitory Concentration (IC50)	185197.53	nM	RL cells	Diffuse large B-cell lymphoma	CVCL_1660
Half Maximal Inhibitory Concentration (IC50)	185912.66	nM	SU-DHL-1 cells	Anaplastic large cell lymphoma	CVCL_0538
Half Maximal Inhibitory Concentration (IC50)	186284.49	nM	CHP-126 cells	Neuroblastoma	CVCL_1123
Half Maximal Inhibitory Concentration (IC50)	189802.11	nM	RPMI-8226 cells	Plasma cell myeloma	CVCL_0014
Half Maximal Inhibitory Concentration (IC50)	19	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	19.42	nM	KGN cells	Ovarian granulosa cell tumor	CVCL_0375
Half Maximal Inhibitory Concentration (IC50)	190163.27	nM	SNU-5 cells	Gastric adenocarcinoma	CVCL_0078
Half Maximal Inhibitory Concentration (IC50)	192.95	nM	NALM-6 cells	B acute lymphoblastic leukemia	CVCL_0092
Half Maximal Inhibitory Concentration (IC50)	19397.28	nM	NCI-H510A cells	Lung small cell carcinoma	CVCL_1565
Half Maximal Inhibitory Concentration (IC50)	19487.71	nM	NB13 cells	Neuroblastoma	CVCL_1443
Half Maximal Inhibitory Concentration (IC50)	195.31	nM	CP66-MEL cells	Melanoma	CVCL_1144
Half Maximal Inhibitory Concentration (IC50)	195596.72	nM	LOUCY cells	Adult T acute lymphoblastic leukemia	CVCL_1380
Half Maximal Inhibitory Concentration (IC50)	195634.48	nM	TALL-1 cells	T acute lymphoblastic leukemia	CVCL_1736
Half Maximal Inhibitory Concentration (IC50)	19754.34	nM	HAL-01 cells	B acute lymphoblastic leukemia	CVCL_1242
Half Maximal Inhibitory Concentration (IC50)	197635.61	nM	ML-2 cells	Acute myeloid leukemia	CVCL_1418
Half Maximal Inhibitory Concentration (IC50)	199.87	nM	697 cells	Childhood B acute lymphoblastic leukemia	CVCL_0079
Half Maximal Inhibitory Concentration (IC50)	>19952.62	nM	Vero C1008 cells	Normal	CVCL_0574	[36]
Half Maximal Inhibitory Concentration (IC50)	199552.63	nM	SCLC-21H cells	Lung small cell carcinoma	CVCL_0024
Half Maximal Inhibitory Concentration (IC50)	2.3	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	2.68	nM	HEK293 cells	Normal	CVCL_0045	[37]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	20	nM	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma	CVCL_0062	[31]
Half Maximal Inhibitory Concentration (IC50)	20.11	nM	NCI-H1648 cells	Lung adenocarcinoma	CVCL_1482
Half Maximal Inhibitory Concentration (IC50)	20.3	nM	OS-RC-2 cells	Clear cell renal cell carcinoma	CVCL_1626
Half Maximal Inhibitory Concentration (IC50)	2000	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[38]
Half Maximal Inhibitory Concentration (IC50)	>20000	nM	Vero C1008 cells	Normal	CVCL_0574	[36]
Half Maximal Inhibitory Concentration (IC50)	20273.33	nM	NCI-H720 cells	Lung carcinoid tumor	CVCL_1583
Half Maximal Inhibitory Concentration (IC50)	203013	nM	LU-134-A cells	Lung small cell carcinoma	CVCL_1387
Half Maximal Inhibitory Concentration (IC50)	203751.07	nM	COLO-824 cells	Breast carcinoma	CVCL_1136
Half Maximal Inhibitory Concentration (IC50)	204.88	nM	CP67-MEL cells	Melanoma	CVCL_1145
Half Maximal Inhibitory Concentration (IC50)	20635.65	nM	Reh cells	B acute lymphoblastic leukemia	CVCL_1650
Half Maximal Inhibitory Concentration (IC50)	208585.49	nM	NB7 cells	Neuroblastoma	CVCL_8824
Half Maximal Inhibitory Concentration (IC50)	21.57	nM	GB-1 cells	Glioblastoma	CVCL_1227
Half Maximal Cell Growth Inhibitory Concentration (GI50)	21.7	nM	RXF 393 cells	Renal carcinoma	CVCL_1673	[39]
Half Maximal Inhibitory Concentration (IC50)	21.7	nM	RXF 393 cells	Renal carcinoma	CVCL_1673	[40]
Half Maximal Effective Concentration (EC50)	2100	nM	Vero C1008 cells	Normal	CVCL_0574	[41]
Half Maximal Effective Concentration (EC50)	2100	nM	Vero C1008 cells	Normal	CVCL_0574	[42]
Half Maximal Inhibitory Concentration (IC50)	211222.91	nM	NB10 cells	Neuroblastoma	CVCL_1441
Half Maximal Inhibitory Concentration (IC50)	214190.97	nM	P30-OHK cells	B acute lymphoblastic leukemia	CVCL_1631
Half Maximal Inhibitory Concentration (IC50)	2166.93	nM	SK-UT-1 cells	Uterine corpus leiomyosarcoma	CVCL_0533
Half Maximal Inhibitory Concentration (IC50)	218851.41	nM	NCI-H82 cells	Lung small cell carcinoma	CVCL_1591
Half Maximal Inhibitory Concentration (IC50)	220259.85	nM	YT cells	Natural killer cell lymphoblastic leukemia	CVCL_1797
Half Maximal Inhibitory Concentration (IC50)	224482.11	nM	TUR cells	Acute monocytic leukemia	CVCL_1775
Half Maximal Inhibitory Concentration (IC50)	2270	nM	NCI-H23 cells	Lung adenocarcinoma	CVCL_1547	[12]
Half Maximal Inhibitory Concentration (IC50)	229876.45	nM	NCI-H2171 cells	Lung small cell carcinoma	CVCL_1536
Half Maximal Inhibitory Concentration (IC50)	23	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	23.57	nM	RXF 393 cells	Renal carcinoma	CVCL_1673
Half Maximal Inhibitory Concentration (IC50)	2300	nM	HCT 116 cells	Colon carcinoma	CVCL_0291	[12]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	2300	nM	MOLM-14 cells	Leukemia	CVCL_7916	[7]
Half Maximal Inhibitory Concentration (IC50)	231338.96	nM	C8166 cells	Leukemia	CVCL_1099
Half Maximal Inhibitory Concentration (IC50)	23146.02	nM	KNS-81-FD cells	Glioblastoma	CVCL_1336
Half Maximal Effective Concentration (EC50)	232	nM	PC-3 cells	Prostate carcinoma	CVCL_0035	[1]
Half Maximal Inhibitory Concentration (IC50)	233997.87	nM	ECC4 cells	Rectal adenocarcinoma	CVCL_1190
Half Maximal Inhibitory Concentration (IC50)	234387.8	nM	NCI-H1694 cells	Lung small cell carcinoma	CVCL_1489
Half Maximal Inhibitory Concentration (IC50)	235260.4	nM	NH-12 cells	Adrenal gland neuroblastoma	CVCL_1605
Half Maximal Inhibitory Concentration (IC50)	235546.18	nM	DG-75 cells	Burkitt lymphoma	CVCL_0244
Half Maximal Inhibitory Concentration (IC50)	2362.84	nM	JVM-2 cells	Mantle cell lymphoma	CVCL_1319
Half Maximal Inhibitory Concentration (IC50)	23674457.42	nM	CTB-1 cells	Diffuse large B-cell lymphoma	CVCL_1149
Half Maximal Inhibitory Concentration (IC50)	23730	nM	A-549 cells	Lung adenocarcinoma	CVCL_0023	[24]
Half Maximal Inhibitory Concentration (IC50)	238724.46	nM	CW-2 cells	Colon adenocarcinoma	CVCL_1151
Half Maximal Inhibitory Concentration (IC50)	238910.5	nM	EW-12 cells	Ewing sarcoma	CVCL_1210
Half Maximal Inhibitory Concentration (IC50)	239736.4	nM	KMOE-2 cells	Erythroleukemia	CVCL_1332
Half Maximal Inhibitory Concentration (IC50)	240.01	nM	DSH1 cells	Bladder carcinoma	CVCL_1182
Half Maximal Inhibitory Concentration (IC50)	240365.82	nM	LU-165 cells	Lung small cell carcinoma	CVCL_1391
Half Maximal Cell Growth Inhibitory Concentration (GI50)	2418	nM	SW620 cells	Colon adenocarcinoma	CVCL_0547	[8]
Half Maximal Inhibitory Concentration (IC50)	2430	nM	DU145 cells	Prostate carcinoma	CVCL_0105	[43]
Half Maximal Inhibitory Concentration (IC50)	243664.19	nM	SHP-77 cells	Small cell lung carcinoma	CVCL_1693
Half Maximal Inhibitory Concentration (IC50)	24775.39	nM	NCI-H2141 cells	Lung small cell carcinoma	CVCL_1534
Half Maximal Inhibitory Concentration (IC50)	25	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	25.86	nM	LC-2-ad cells	Lung adenocarcinoma	CVCL_1373
Half Maximal Inhibitory Concentration (IC50)	2500	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	251188.64	nM	HEK293 cells	Normal	CVCL_0045	[22]
Half Maximal Inhibitory Concentration (IC50)	255170	nM	COR-L88 cells	Lung small cell carcinoma	CVCL_1141
Half Maximal Inhibitory Concentration (IC50)	2570	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[12]
Half Maximal Inhibitory Concentration (IC50)	2575.51	nM	LB771-HNC cells	Head and neck squamous cell carcinoma	CVCL_1369
Half Maximal Inhibitory Concentration (IC50)	258742.92	nM	HCC2218 cells	Breast ductal carcinoma	CVCL_1263
Half Maximal Inhibitory Concentration (IC50)	262121.73	nM	NCI-H1417 cells	Lung small cell carcinoma	CVCL_1469
Half Maximal Inhibitory Concentration (IC50)	262929.78	nM	SNU-C1 cells	Colon adenocarcinoma	CVCL_1708
Half Maximal Inhibitory Concentration (IC50)	263.03	nM	HEK293 cells	Normal	CVCL_0045	[33]
Half Maximal Inhibitory Concentration (IC50)	26341686.46	nM	CA46 cells	Burkitt lymphoma	CVCL_1101
Half Maximal Inhibitory Concentration (IC50)	264.39	nM	HCE-4 cells	Esophageal squamous cell carcinoma	CVCL_1271
Half Maximal Inhibitory Concentration (IC50)	26675.27	nM	MOLT-4 cells	Adult T acute lymphoblastic leukemia	CVCL_0013
Half Maximal Inhibitory Concentration (IC50)	27.3	nM	KS-1 cells	Glioblastoma	CVCL_1343
Half Maximal Cell Growth Inhibitory Concentration (GI50)	270	nM	CHL cells	Normal	CVCL_0212	[7]
Half Maximal Inhibitory Concentration (IC50)	270368	nM	U266B1 cells	Plasma cell myeloma	CVCL_0566
Half Maximal Inhibitory Concentration (IC50)	27142.15	nM	OMC-1 cells	Cervical squamous cell carcinoma	CVCL_1623
Half Maximal Inhibitory Concentration (IC50)	271947.76	nM	Kasumi-1 cells	Myeloid leukemia with maturation	CVCL_0589
Half Maximal Inhibitory Concentration (IC50)	27324.51	nM	LC-1F cells	Lung squamous cell carcinoma	CVCL_1372
Half Maximal Inhibitory Concentration (IC50)	28.32	nM	ETK-1 cells	Cholangiocarcinoma	CVCL_1206
Half Maximal Inhibitory Concentration (IC50)	28162.8	nM	NCI-H1304 cells	Lung small cell carcinoma	CVCL_1462
Half Maximal Inhibitory Concentration (IC50)	282984.46	nM	IM-9 cells	Multiple myeloma	CVCL_1305
Half Maximal Inhibitory Concentration (IC50)	285.37	nM	MZ2-MEL cells	Melanoma	CVCL_1435
Half Maximal Inhibitory Concentration (IC50)	2858439.14	nM	NCI-H1522 cells	Lung small cell carcinoma	CVCL_1474
Half Maximal Inhibitory Concentration (IC50)	28650.96	nM	BC1 cells	Primary effusion lymphoma	CVCL_1079
Half Maximal Inhibitory Concentration (IC50)	2866.16	nM	NCC-IT cells	Testicular embryonal carcinoma	CVCL_1451
Half Maximal Inhibitory Concentration (IC50)	2875.52	nM	NCI-H2126 cells	Lung large cell carcinoma	CVCL_1532
Half Maximal Inhibitory Concentration (IC50)	29	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	29	nM	HCC366 cells	Lung adenosquamous carcinoma	CVCL_2059	[44]
Half Maximal Inhibitory Concentration (IC50)	29.27	nM	SW 954 cells	Vulva squamous carcinoma	CVCL_1732
Half Maximal Inhibitory Concentration (IC50)	290747.44	nM	SUP-T1 cells	T lymphoblastic lymphoma	CVCL_1714
Half Maximal Inhibitory Concentration (IC50)	291.23	nM	BL-41 cells	Burkitt lymphoma	CVCL_1087
Half Maximal Cell Growth Inhibitory Concentration (GI50)	2927	nM	Daoy cells	Medulloblastoma	CVCL_1167	[8]
Half Maximal Inhibitory Concentration (IC50)	293449.92	nM	SK-MEL-1 cells	Metastatic melanoma	CVCL_0068
Half Maximal Inhibitory Concentration (IC50)	295228.02	nM	SIMA cells	Adrenal gland neuroblastoma	CVCL_1695
Half Maximal Inhibitory Concentration (IC50)	29625.31	nM	NCI-H64 cells	Lung small cell carcinoma	CVCL_1573
Half Maximal Inhibitory Concentration (IC50)	29629.19	nM	MOLT-16 cells	T acute lymphoblastic leukemia	CVCL_1424
Half Maximal Inhibitory Concentration (IC50)	296371.28	nM	HL-60 cells	Adult acute myeloid leukemia	CVCL_0002
Half Maximal Inhibitory Concentration (IC50)	299463.04	nM	ES5 cells	Ewing sarcoma	CVCL_1201
Half Maximal Cell Growth Inhibitory Concentration (GI50)	3	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	3	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Inhibitory Concentration (IC50)	3.2	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	30.03	nM	Becker cells	Astrocytoma	CVCL_1093
Half Maximal Cell Growth Inhibitory Concentration (GI50)	3000	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	3000	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Inhibitory Concentration (IC50)	3057.41	nM	Calu-6 cells	Lung adenocarcinoma	CVCL_0236
Half Maximal Inhibitory Concentration (IC50)	30765.99	nM	U-87MG ATCC cells	Glioblastoma	CVCL_0022
Half Maximal Inhibitory Concentration (IC50)	308019.78	nM	DMS-79 cells	Small cell lung carcinoma	CVCL_1178
Half Maximal Inhibitory Concentration (IC50)	31.19	nM	MZ1-PC cells	Pancreatic ductal adenocarcinoma	CVCL_1434
Half Maximal Inhibitory Concentration (IC50)	31.93	nM	ES6 cells	Ewing sarcoma	CVCL_1202
Half Maximal Inhibitory Concentration (IC50)	3118.86	nM	SK-LMS-1 cells	Vulvar leiomyosarcoma	CVCL_0628
Half Maximal Inhibitory Concentration (IC50)	31268.56	nM	GAK cells	Vulvar melanoma	CVCL_1225
Half Maximal Inhibitory Concentration (IC50)	314.2	nM	HuTu 80 cells	Duodenal adenocarcinoma	CVCL_1301
Half Maximal Inhibitory Concentration (IC50)	315.03	nM	LOX IMVI cells	Melanoma	CVCL_1381
Half Maximal Inhibitory Concentration (IC50)	316227.77	nM	CHO cells	Normal	CVCL_0213	[22]
Half Maximal Inhibitory Concentration (IC50)	319.31	nM	no-10 cells	Glioblastoma	CVCL_3075
Half Maximal Inhibitory Concentration (IC50)	319165.25	nM	SCH cells	Gastric choriocarcinoma	CVCL_1687
Half Maximal Inhibitory Concentration (IC50)	32	nM	NCI-H2286 cells	Lung squamous cell carcinoma	CVCL_1545	[44]
Half Maximal Inhibitory Concentration (IC50)	320838.86	nM	Lu-65 cells	Lung giant cell carcinoma	CVCL_1392
Half Maximal Inhibitory Concentration (IC50)	32125.21	nM	ES8 cells	Ewing sarcoma	CVCL_1204
Half Maximal Inhibitory Concentration (IC50)	32332.47	nM	HCC1599 cells	Breast ductal carcinoma	CVCL_1256
Half Maximal Inhibitory Concentration (IC50)	324287.67	nM	NCI-H1963 cells	Lung small cell carcinoma	CVCL_1510
Half Maximal Inhibitory Concentration (IC50)	324769.27	nM	LNCaP-Clone-FGC cells	Prostate carcinoma	CVCL_1379
Half Maximal Effective Concentration (EC50)	33	nM	BxPC-3 CDX model cells	Pancreatic ductal adenocarcinoma	CVCL_0186	[1]
Half Maximal Inhibitory Concentration (IC50)	33.3	nM	NCI-H2286 cells	Lung squamous cell carcinoma	CVCL_1545	[45]
Half Maximal Inhibitory Concentration (IC50)	330749.4	nM	EW-18 cells	Ewing sarcoma	CVCL_1213
Half Maximal Inhibitory Concentration (IC50)	331638	nM	WSU-NHL cells	Diffuse large B-cell lymphoma	CVCL_1793
Half Maximal Inhibitory Concentration (IC50)	335610.75	nM	P31-FUJ cells	Acute myeloid leukemia	CVCL_1632
Half Maximal Inhibitory Concentration (IC50)	339.97	nM	Karpas-422 cells	Diffuse large B-cell lymphoma	CVCL_1325
Half Maximal Inhibitory Concentration (IC50)	34.87	nM	KURAMOCHI cells	Ovarian serous adenocarcinoma	CVCL_1345
Half Maximal Inhibitory Concentration (IC50)	34311.75	nM	EB-3 cells	Burkitt lymphoma	CVCL_1185
Half Maximal Inhibitory Concentration (IC50)	3469.15	nM	ARH-77 cells	Leukemia	CVCL_1072
Half Maximal Inhibitory Concentration (IC50)	349.8	nM	SW684 cells	Fibrosarcoma	CVCL_1726
Half Maximal Inhibitory Concentration (IC50)	35.48	nM	CGTH-W-1 cells	Thyroid gland squamous cell carcinoma	CVCL_1120
Half Maximal Inhibitory Concentration (IC50)	350804.12	nM	ES7 cells	Ewing sarcoma	CVCL_1203
Half Maximal Inhibitory Concentration (IC50)	354.1	nM	SF-126 cells	Glioblastoma	CVCL_1688
Half Maximal Inhibitory Concentration (IC50)	3580	nM	HCT 116 cells	Colon carcinoma	CVCL_0291	[24]
Half Maximal Inhibitory Concentration (IC50)	35805.16	nM	HCC1187 cells	Breast ductal carcinoma	CVCL_1247
Half Maximal Cell Growth Inhibitory Concentration (GI50)	3600	nM	MV4-11 cells	Childhood acute monocytic leukemia	CVCL_0064	[7]
Half Maximal Inhibitory Concentration (IC50)	3600	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	36194.28	nM	SK-PN-DW cells	Primitive neuroectodermal tumor	CVCL_1703
Half Maximal Inhibitory Concentration (IC50)	362.24	nM	D-263MG cells	Glioblastoma	CVCL_1154
Half Maximal Inhibitory Concentration (IC50)	3638.47	nM	NB17 cells	Neuroblastoma	CVCL_1445
Half Maximal Inhibitory Concentration (IC50)	368852.56	nM	HD-MY-Z cells	Acute myeloid leukemia	CVCL_1273
Half Maximal Cell Growth Inhibitory Concentration (GI50)	3700	nM	HCT 116 cells	Colon carcinoma	CVCL_0291	[31]
Half Maximal Inhibitory Concentration (IC50)	37233.8	nM	JVM-3 cells	B-cell prolymphocytic leukemia	CVCL_1320
Half Maximal Inhibitory Concentration (IC50)	3732.46	nM	A-253 cells	Submandibular gland squamous cell carcinoma	CVCL_1060
Half Maximal Inhibitory Concentration (IC50)	374.33	nM	OVCAR-4 cells	Ovarian adenocarcinoma	CVCL_1627
Half Maximal Inhibitory Concentration (IC50)	37994.64	nM	HCC2157 cells	Breast ductal carcinoma	CVCL_1261
Half Maximal Inhibitory Concentration (IC50)	3800	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	38100.9	nM	A4-Fuk cells	B acute lymphoblastic leukemia	CVCL_1064
Half Maximal Inhibitory Concentration (IC50)	385.99	nM	BB49-HNC cells	Floor of mouth squamous cell carcinoma	CVCL_1077
Half Maximal Cell Growth Inhibitory Concentration (GI50)	39	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Inhibitory Concentration (IC50)	39.02	nM	VA-ES-BJ cells	Epithelioid sarcoma	CVCL_1785
Half Maximal Inhibitory Concentration (IC50)	3900	nM	MDA-MB-435S cells	Amelanotic melanoma	CVCL_0622	[12]
Half Maximal Inhibitory Concentration (IC50)	393433.08	nM	Daudi cells	Burkitt lymphoma	CVCL_0008
Half Maximal Inhibitory Concentration (IC50)	395422.57	nM	NCI-H1155 cells	Lung large cell carcinoma	CVCL_1456
Half Maximal Inhibitory Concentration (IC50)	397005.84	nM	NB14 cells	Neuroblastoma	CVCL_1444
Half Maximal Inhibitory Concentration (IC50)	398107.17	nM	HEK293 cells	Normal	CVCL_0045	[22]
Half Maximal Inhibitory Concentration (IC50)	398107.17	nM	CHO cells	Normal	CVCL_0213	[22]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	4	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Inhibitory Concentration (IC50)	40.49	nM	MPP-89 cells	Pleural epithelioid mesothelioma	CVCL_1427
Half Maximal Inhibitory Concentration (IC50)	>40000	nM	L02 cells	Cervical carcinoma	CVCL_6926	[23]
Half Maximal Inhibitory Concentration (IC50)	402262.56	nM	SK-N-DZ cells	Neuroblastoma	CVCL_1701
Half Maximal Inhibitory Concentration (IC50)	40285.15	nM	COR-L279 cells	Lung small cell carcinoma	CVCL_1140
Half Maximal Inhibitory Concentration (IC50)	41.61	nM	SW872 cells	Liposarcoma	CVCL_1730
Half Maximal Inhibitory Concentration (IC50)	41908.6	nM	DEL/BVR cells	Anaplastic large cell lymphoma	CVCL_1170
Half Maximal Inhibitory Concentration (IC50)	419629.01	nM	NCI-H69 cells	Small cell lung carcinoma	CVCL_1579
Half Maximal Inhibitory Concentration (IC50)	42016.27	nM	NCI-H1395 cells	Lung adenocarcinoma	CVCL_1467
Half Maximal Inhibitory Concentration (IC50)	4276.85	nM	OPM-2 cells	Plasma cell myeloma	CVCL_1625
Half Maximal Inhibitory Concentration (IC50)	429.51	nM	ONS-76 cells	Medulloblastoma	CVCL_1624
Half Maximal Inhibitory Concentration (IC50)	43081.77	nM	MHH-NB-11 cells	Neuroblastoma	CVCL_1412
Half Maximal Inhibitory Concentration (IC50)	434498.72	nM	MC/CAR cells	Normal	CVCL_1397
Half Maximal Inhibitory Concentration (IC50)	43484.65	nM	NCI-H2107 cells	Lung small cell carcinoma	CVCL_1527
Half Maximal Inhibitory Concentration (IC50)	4364.54	nM	MV4-11 cells	Childhood acute monocytic leukemia	CVCL_0064
Half Maximal Effective Concentration (EC50)	44	nM	MDA-MB-231 cells (5T4 overexpression)	Breast adenocarcinoma	CVCL_0062	[1]
Half Maximal Inhibitory Concentration (IC50)	44.35	nM	SNB-75 cells	Glioblastoma	CVCL_1706
Half Maximal Inhibitory Concentration (IC50)	44.74	nM	PSN1 cells	Pancreatic adenocarcinoma	CVCL_1644
Half Maximal Inhibitory Concentration (IC50)	44336.04	nM	NEC8 cells	Testicular embryonal carcinoma	CVCL_1604
Half Maximal Inhibitory Concentration (IC50)	4499.54	nM	SR cells	Leukemia	CVCL_1711
Half Maximal Inhibitory Concentration (IC50)	450	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[46]
Half Maximal Inhibitory Concentration (IC50)	46.09	nM	LB831-BLC cells	Bladder carcinoma	CVCL_1370
Half Maximal Inhibitory Concentration (IC50)	4600	nM	DLD-1 cells	Colon adenocarcinoma	CVCL_0248	[27]
Half Maximal Inhibitory Concentration (IC50)	4608.45	nM	KG-1 cells	Adult acute myeloid leukemia	CVCL_0374
Half Maximal Inhibitory Concentration (IC50)	46225.8	nM	COLO-684 cells	Endometrial adenocarcinoma	CVCL_1132
Half Maximal Inhibitory Concentration (IC50)	47.24	nM	MFH-ino cells	Pleomorphic sarcoma	CVCL_1407
Half Maximal Inhibitory Concentration (IC50)	47.61	nM	TGBC24TKB cells	Gallbladder carcinoma	CVCL_1770
Half Maximal Effective Concentration (EC50)	470	nM	HEK293 cells	Normal	CVCL_0045	[47]
Half Maximal Effective Concentration (EC50)	4700	nM	Huh-7 cells	Adult hepatocellular carcinoma	CVCL_0336	[41]
Half Maximal Inhibitory Concentration (IC50)	479.11	nM	MZ7-mel cells	Melanoma	CVCL_1436
Half Maximal Inhibitory Concentration (IC50)	48474.84	nM	LS-411N cells	Cecum adenocarcinoma	CVCL_1385
Half Maximal Inhibitory Concentration (IC50)	491.1	nM	RCC10RGB cells	Renal cell carcinoma	CVCL_1647
Half Maximal Inhibitory Concentration (IC50)	491.33	nM	BOKU cells	Cervical squamous cell carcinoma	CVCL_1089
Half Maximal Cell Growth Inhibitory Concentration (GI50)	5	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Inhibitory Concentration (IC50)	5.1	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	5.891	nM	TE-15 cells	Esophageal squamous cell carcinom	CVCL_1763
Half Maximal Inhibitory Concentration (IC50)	50.95	nM	A388 cells	Skin squamous cell carcinoma	CVCL_1063
Half Maximal Inhibitory Concentration (IC50)	500	nM	Huh-7.5.1 cells	Hepatocellular carcinoma	CVCL_E049	[41]
Half Maximal Inhibitory Concentration (IC50)	>500	nM	FDC-P1 cells	Normal	CVCL_2039	[48]
Half Maximal Inhibitory Concentration (IC50)	>5000	nM	Hep-G2 cells	Hepatoblastoma	CVCL_0027	[34]
Half Maximal Inhibitory Concentration (IC50)	50118.72	nM	CHO cells	Normal	CVCL_0213	[22]
Half Maximal Inhibitory Concentration (IC50)	50118.72	nM	CHO cells	Normal	CVCL_0213	[22]
Half Maximal Inhibitory Concentration (IC50)	502.28	nM	no-11 cells	Glioblastoma	CVCL_3076
Half Maximal Inhibitory Concentration (IC50)	50299.95	nM	HT cells	Diffuse large B-cell lymphoma	CVCL_1290
Half Maximal Inhibitory Concentration (IC50)	503.02	nM	IST-SL2 cells	Lung small cell carcinoma	CVCL_1314
Half Maximal Inhibitory Concentration (IC50)	50436.29	nM	SK-N-FI cells	Neuroblastoma	CVCL_1702
Half Maximal Inhibitory Concentration (IC50)	50497.21	nM	COLO 320HSR cells	Colon adenocarcinoma	CVCL_0220
Half Maximal Cell Growth Inhibitory Concentration (GI50)	5114	nM	SK-N-MC cells	Neuroepithelioma	CVCL_0530	[8]
Half Maximal Inhibitory Concentration (IC50)	5147	nM	MDA-MB-435 cells	Amelanotic melanoma	CVCL_0417	[25]
Half Maximal Inhibitory Concentration (IC50)	5230	nM	HCT 116 cells	Colon carcinoma	CVCL_0291	[23]
Half Maximal Inhibitory Concentration (IC50)	52550.21	nM	NCI-H526 cells	Lung small cell carcinoma	CVCL_1569
Half Maximal Inhibitory Concentration (IC50)	529.66	nM	RKO cells	Colon carcinoma	CVCL_0504
Half Maximal Inhibitory Concentration (IC50)	530	nM	Huh-7.5.1 cells	Hepatocellular carcinoma	CVCL_E049	[41]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	5300	nM	HEL cells	Erythroleukemia	CVCL_0001	[7]
Half Maximal Inhibitory Concentration (IC50)	536.09	nM	HT-144 cells	Melanoma	CVCL_0318
Half Maximal Inhibitory Concentration (IC50)	53931.19	nM	NCI-H748 cells	Lung small cell carcinoma	CVCL_1588
Half Maximal Inhibitory Concentration (IC50)	54.37	nM	BB30-HNC cells	Head and neck squamous cell carcinoma	CVCL_1076
Half Maximal Inhibitory Concentration (IC50)	54405.16	nM	AM-38 cells	Glioblastoma	CVCL_1070
Half Maximal Effective Concentration (EC50)	5460	nM	Vero C1008 cells	Normal	CVCL_0574	[41]
Half Maximal Effective Concentration (EC50)	5468	nM	Vero C1008 cells	Normal	CVCL_0574	[32]
Half Maximal Effective Concentration (EC50)	55	nM	CAKI-2 cells	Renal carcinoma	CVCL_0235	[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	565	nM	LN-18 cells	Glioblastoma	CVCL_0392	[8]
Half Maximal Inhibitory Concentration (IC50)	5700	nM	EC-RF24 cells	Normal	CVCL_AX74	[49]
Half Maximal Inhibitory Concentration (IC50)	5861.54	nM	OCI-AML-2 cells	Adult acute myeloid leukemia	CVCL_1619
Half Maximal Inhibitory Concentration (IC50)	58952.62	nM	KM12 cells	Colon adenocarcinoma	CVCL_1331
Half Maximal Inhibitory Concentration (IC50)	58956.45	nM	MRK-nu-1 cells	Breast carcinoma	CVCL_1428
Half Maximal Inhibitory Concentration (IC50)	59070.7	nM	ES3 cells	Ewing sarcoma	CVCL_1199
Half Maximal Inhibitory Concentration (IC50)	6	nM	HEK293 cells	Normal	CVCL_0045	[50]
Half Maximal Inhibitory Concentration (IC50)	6.129	nM	NOS-1 cells	Osteosarcoma	CVCL_1610
Half Maximal Inhibitory Concentration (IC50)	6.298	nM	D-336MG cells	Glioblastoma	CVCL_1156
Half Maximal Inhibitory Concentration (IC50)	6.7	nM	C2C12 cells	Normal	CVCL_0188	[21]
Half Maximal Inhibitory Concentration (IC50)	6000	nM	THP-1 cells	Childhood acute monocytic leukemia	CVCL_0006	[51]
Half Maximal Inhibitory Concentration (IC50)	61.18	nM	GI-ME-N cells	Neuroblastoma	CVCL_1232
Half Maximal Inhibitory Concentration (IC50)	61.64	nM	TGBC1TKB cells	Gallbladder undifferentiated carcinoma	CVCL_1769
Half Maximal Inhibitory Concentration (IC50)	6125.19	nM	D-247MG cells	Gliosarcoma	CVCL_1153
Half Maximal Inhibitory Concentration (IC50)	61920.23	nM	ATN-1 cells	T acute lymphoblastic leukemia	CVCL_1073
Half Maximal Cell Growth Inhibitory Concentration (GI50)	62.3	nM	DU145 cells	Prostate carcinoma	CVCL_0105	[39]
Half Maximal Inhibitory Concentration (IC50)	62.3	nM	DU145 cells	Prostate carcinoma	CVCL_0105	[40]
Half Maximal Inhibitory Concentration (IC50)	62408.91	nM	SK-MM-2 cells	Plasma cell myeloma	CVCL_1699
Half Maximal Inhibitory Concentration (IC50)	627.6	nM	NCI-H446 cells	Lung small cell carcinoma	CVCL_1562
Half Maximal Inhibitory Concentration (IC50)	62861.13	nM	Karpas-299 cells/Karpas BVR cells	ALK-positive anaplastic large cell lymphoma	CVCL_1324
Half Maximal Inhibitory Concentration (IC50)	63	nM	HEK293 cells	Normal	CVCL_0045	[52]
Half Maximal Inhibitory Concentration (IC50)	63.57	nM	TE-10 cells	Esophageal squamous cell carcinoma	CVCL_1760
Half Maximal Cell Growth Inhibitory Concentration (GI50)	644	nM	MOLT-4 cells	Adult T acute lymphoblastic leukemia	CVCL_0013	[8]
Half Maximal Inhibitory Concentration (IC50)	6485.58	nM	DJM-1 cells	Skin squamous cell carcinoma	CVCL_1172
Half Maximal Inhibitory Concentration (IC50)	64941.31	nM	NCI-H2081 cells	Lung small cell carcinoma	CVCL_1522
Half Maximal Inhibitory Concentration (IC50)	65216.01	nM	RPMI-8402 cells	T acute lymphoblastic leukemia	CVCL_1667
Half Maximal Inhibitory Concentration (IC50)	6589	nM	BaF3 cells	Normal	CVCL_0161	[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	6610	nM	Malme-3M cells	Melanoma	CVCL_1438	[31]
Half Maximal Inhibitory Concentration (IC50)	67069.67	nM	DB cells	Diffuse large B-cell lymphoma	CVCL_1168
Half Maximal Inhibitory Concentration (IC50)	7.4	nM	FDC-P1 cells	Normal	CVCL_2039	[48]
Half Maximal Inhibitory Concentration (IC50)	70646.46	nM	KE-37 cells	T acute lymphoblastic leukemia	CVCL_1327
Half Maximal Inhibitory Concentration (IC50)	710	nM	NHDF cells	Normal	Undisclosed	[24]
Half Maximal Inhibitory Concentration (IC50)	71280.8	nM	NB1 cells	Neuroblastoma	CVCL_8812
Half Maximal Inhibitory Concentration (IC50)	72.84	nM	A498 cells	Renal carcinoma	CVCL_1056
Half Maximal Inhibitory Concentration (IC50)	7270.67	nM	RPMI-6666 cells	Normal	CVCL_1665
Half Maximal Inhibitory Concentration (IC50)	73364.41	nM	DMS 114 cells	Lung small cell carcinoma	CVCL_1174
Half Maximal Inhibitory Concentration (IC50)	74.13	nM	SH-SY5Y cells	Bone marrow neuroblastoma	CVCL_0019	[33]
Half Maximal Inhibitory Concentration (IC50)	744.69	nM	MHH-PREB-1 cells	B-cell non-Hodgkin lymphoma	CVCL_1413
Half Maximal Inhibitory Concentration (IC50)	7440	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[43]
Half Maximal Inhibitory Concentration (IC50)	7500	nM	Hep-G2 cells	Hepatoblastoma	CVCL_0027	[25]
Half Maximal Inhibitory Concentration (IC50)	75008.92	nM	COLO-800 cells	Cutaneous melanoma	CVCL_1135
Half Maximal Inhibitory Concentration (IC50)	7516.71	nM	KARPAS-45 cells	T acute lymphoblastic leukemia	CVCL_1326
Half Maximal Inhibitory Concentration (IC50)	7547.82	nM	LP-1 cells	Plasma cell myeloma	CVCL_0012
Half Maximal Inhibitory Concentration (IC50)	761.78	nM	EW-16 cells	Ewing sarcoma	CVCL_1212
Half Maximal Inhibitory Concentration (IC50)	7657.87	nM	RS4 11 cells	Adult B acute lymphoblastic leukemia	CVCL_0093
Half Maximal Inhibitory Concentration (IC50)	76681.77	nM	NCI-H1770 cells	Lung non-small cell carcinoma	CVCL_1493
Half Maximal Inhibitory Concentration (IC50)	76839.44	nM	NCI-H226 cells	Pleural epithelioid mesothelioma	CVCL_1544
Half Maximal Inhibitory Concentration (IC50)	78.58	nM	TE-11 cells	Esophageal squamous cell carcinoma	CVCL_1761
Half Maximal Inhibitory Concentration (IC50)	7800	nM	NCI-H661 cells	Lung large cell carcinoma	CVCL_1577	[27]
Half Maximal Inhibitory Concentration (IC50)	781.65	nM	EW-24 cells	Ewing sarcoma	CVCL_1215
Half Maximal Inhibitory Concentration (IC50)	79190.71	nM	IST-SL1 cells	Lung small cell carcinoma	CVCL_1313
Half Maximal Inhibitory Concentration (IC50)	79461.37	nM	EC-GI-10 cells	Esophageal squamous cell carcinoma	CVCL_1187
Half Maximal Cell Growth Inhibitory Concentration (GI50)	8	nM	Jurkat cells	T acute lymphoblastic leukemia	CVCL_0065	[8]
Half Maximal Cell Growth Inhibitory Concentration (GI50)	8	nM	BaF3 cells	Normal	CVCL_0161	[7]
Half Maximal Inhibitory Concentration (IC50)	8	nM	BaF3 cells	Normal	CVCL_0161	[5]
Half Maximal Inhibitory Concentration (IC50)	80	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[51]
Half Maximal Inhibitory Concentration (IC50)	8050	nM	MCF7-F (fulvestrant resistant) cells	Invasive breast carcinoma	CVCL_0031	[26]
Half Maximal Inhibitory Concentration (IC50)	80858.04	nM	MSTO-211H cells	Pleural biphasic mesothelioma	CVCL_1430
Half Maximal Inhibitory Concentration (IC50)	81908.52	nM	LS1034 cells	Cecum adenocarcinoma	CVCL_1382
Half Maximal Inhibitory Concentration (IC50)	82.27	nM	BB65-RCC cells	Renal cell carcinoma	CVCL_1078
Half Maximal Inhibitory Concentration (IC50)	8200	nM	A-549 cells	Lung adenocarcinoma	CVCL_0023	[27]
Half Maximal Inhibitory Concentration (IC50)	8216.52	nM	DU-4475 cells	Breast adenocarcinoma	CVCL_1183
Half Maximal Inhibitory Concentration (IC50)	825.08	nM	LB373-MEL-D cells	Melanoma	CVCL_1367
Half Maximal Inhibitory Concentration (IC50)	8270.66	nM	MONO-MAC-6 cells	Acute monocytic leukemia	CVCL_1426
Half Maximal Inhibitory Concentration (IC50)	83.08	nM	C2BBe1 cells	Colon adenocarcinoma	CVCL_1096
Half Maximal Inhibitory Concentration (IC50)	8370	nM	A-549 cells	Lung adenocarcinoma	CVCL_0023	[23]
Half Maximal Inhibitory Concentration (IC50)	85.52	nM	IST-MES1 cells	Pleural epithelioid mesothelioma	CVCL_1311
Half Maximal Inhibitory Concentration (IC50)	8561.28	nM	SNU-16 cells	Gastric adenocarcinoma	CVCL_0076
Half Maximal Inhibitory Concentration (IC50)	85775.46	nM	CMK cells	Down syndrome	CVCL_0216
Half Maximal Inhibitory Concentration (IC50)	86439.18	nM	GOTO cells	Adrenal gland neuroblastoma	CVCL_1234
Half Maximal Inhibitory Concentration (IC50)	8728.05	nM	SJSA-1 cells	Osteosarcoma	CVCL_1697
Half Maximal Inhibitory Concentration (IC50)	874.8	nM	HeLa cells	Endocervical adenocarcinoma	CVCL_0030	[21]
Half Maximal Inhibitory Concentration (IC50)	875.32	nM	TE-9 cells	Esophageal squamous cell carcinoma	CVCL_1767
Half Maximal Inhibitory Concentration (IC50)	8793.07	nM	MMAC-SF cells	Melanoma	CVCL_1420
Half Maximal Cell Growth Inhibitory Concentration (GI50)	880	nM	HCT 116 cells	Colon carcinoma	CVCL_0291	[8]
Half Maximal Inhibitory Concentration (IC50)	8891.55	nM	SK-NEP-1 cells	Ewing sarcoma	CVCL_0631
Half Maximal Inhibitory Concentration (IC50)	8965.29	nM	J-RT3-T3-5 cells	T acute lymphoblastic leukemi	CVCL_1316
Half Maximal Cell Growth Inhibitory Concentration (GI50)	898	nM	SW1088 cells	Astrocytoma	CVCL_1715	[8]
Half Maximal Inhibitory Concentration (IC50)	8980	nM	KG-1a cells	Leukemia	CVCL_1824	[2]
Half Maximal Inhibitory Concentration (IC50)	8990	nM	NCI-H460 cells	Lung large cell carcinoma	CVCL_0459	[12]
Half Maximal Inhibitory Concentration (IC50)	9.887	nM	LB1047-RCC cells	Renal cell carcinoma	CVCL_1364
Half Maximal Inhibitory Concentration (IC50)	9.912	nM	LB996-RCC cells	Renal cell carcinoma	CVCL_1371
Half Maximal Cell Growth Inhibitory Concentration (GI50)	90	nM	NCI-H460 cells	Lung large cell carcinoma	CVCL_0459	[8]
Half Maximal Inhibitory Concentration (IC50)	90	nM	BaF3 cells	Normal	CVCL_0161	[6]
Half Maximal Inhibitory Concentration (IC50)	900	nM	T-47D cells	Invasive breast carcinoma	CVCL_0553	[12]
Half Maximal Inhibitory Concentration (IC50)	9017.34	nM	SKM-1 cells	Acute myeloid leukemia	CVCL_0098
Half Maximal Inhibitory Concentration (IC50)	9020.12	nM	LB2241-RCC cells	Renal cell carcinoma	CVCL_1365
Half Maximal Inhibitory Concentration (IC50)	9024.93	nM	SIG-M5 cells	Acute myeloid leukemia	CVCL_1694
Half Maximal Inhibitory Concentration (IC50)	90770.11	nM	KM-H2 cells	Hodgkin lymphoma	CVCL_1330
Half Maximal Inhibitory Concentration (IC50)	91553.27	nM	NOMO-1 cells	Acute monocytic leukemia	CVCL_1609
Half Maximal Inhibitory Concentration (IC50)	91577.72	nM	EW-3 cells	Ewing sarcoma	CVCL_1216
Half Maximal Inhibitory Concentration (IC50)	92114.28	nM	MHH-CALL-2 cells	B acute lymphoblastic leukemia	CVCL_1409
Half Maximal Inhibitory Concentration (IC50)	92214.37	nM	LC4-1 cells	B acute lymphoblastic leukemia	CVCL_1374
Half Maximal Inhibitory Concentration (IC50)	92307	nM	MDA-MB-134-VI cells	Breast lobular carcinoma	CVCL_0617
Half Maximal Inhibitory Concentration (IC50)	92548.33	nM	D283 Med cells	Medulloblastoma	CVCL_1155
Half Maximal Inhibitory Concentration (IC50)	9277.93	nM	EVSA-T cells	Breast carcinoma	CVCL_1207
Half Maximal Inhibitory Concentration (IC50)	93062.84	nM	U-698-M cells	Lymphoblastic lymphoma	CVCL_0017
Half Maximal Inhibitory Concentration (IC50)	93374.19	nM	HH cells	T-cell non-Hodgkin lymphoma	CVCL_1280
Half Maximal Inhibitory Concentration (IC50)	9355.46	nM	GT3TKB cells	Lung squamous cell carcinoma	CVCL_1237
Half Maximal Inhibitory Concentration (IC50)	96.56	nM	GCIY cells	Gastric adenocarcinoma	CVCL_1228
Half Maximal Cell Growth Inhibitory Concentration (GI50)	9700	nM	K-562 cells	Chronic myelogenous leukemia	CVCL_0004	[9]
Half Maximal Inhibitory Concentration (IC50)	984.52	nM	A3-KAW cells	Diffuse large B-cell lymphoma	CVCL_1062
Half Maximal Inhibitory Concentration (IC50)	9922.59	nM	NB6 cells	Neuroblastoma	CVCL_8823
Half Maximal Cell Growth Inhibitory Concentration (GI50)	9940	nM	BaF3 cells	Normal	CVCL_0161	[7]

Each Antibody-drug Conjugate Related to This Payload

References

Ref 1	Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors. J Med Chem. 2016 Apr 28;59(8):3886-905. doi: 10.1021/acs.jmedchem.6b00087. Epub 2016 Apr 15.
Ref 2	Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells. Bioorg Med Chem Lett. 2018 Feb 15;28(4):700-706. doi: 10.1016/j.bmcl.2018.01.011. Epub 2018 Jan 12.
Ref 3	Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. J Med Chem. 2021 Jun 10;64(11):7434-7452. doi: 10.1021/acs.jmedchem.1c00082. Epub 2021 May 19.
Ref 4	Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. doi: 10.1021/acs.jmedchem.0c00967. Epub 2020 Jul 23.
Ref 5	Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013 Feb 14;56(3):879-94. doi: 10.1021/jm301581y. Epub 2013 Jan 28.
Ref 6	Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A. J Med Chem. 2016 Feb 11;59(3):1184-96. doi: 10.1021/acs.jmedchem.5b01841. Epub 2016 Jan 27.
Ref 7	Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia. J Med Chem. 2016 Mar 10;59(5):1984-2004. doi: 10.1021/acs.jmedchem.5b01618. Epub 2016 Feb 5.
Ref 8	Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). J Med Chem. 2018 Jun 14;61(11):4704-4719. doi: 10.1021/acs.jmedchem.8b00164. Epub 2018 Apr 17.
Ref 9	Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety. J Med Chem. 2022 Aug 25;65(16):10898-10919. doi: 10.1021/acs.jmedchem.1c01853. Epub 2022 Aug 9.
Ref 10	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. doi: 10.1016/j.bmcl.2009.10.085. Epub 2009 Oct 23.
Ref 11	Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm. 2019 Apr 18;10(6):974-984. doi: 10.1039/c8md00412a. eCollection 2019 Jun 1.
Ref 12	Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. J Med Chem. 2013 Apr 25;56(8):3281-95. doi: 10.1021/jm301824k. Epub 2013 Apr 10.
Ref 13	Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. doi: 10.1021/acs.jmedchem.9b01264. Epub 2019 Oct 2.
Ref 14	Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation. Eur J Med Chem. 2021 Nov 5;223:113645. doi: 10.1016/j.ejmech.2021.113645. Epub 2021 Jun 25.
Ref 15	RITA Mimics: Synthesis and Mechanistic Evaluation of Asymmetric Linked Trithiazoles. ACS Med Chem Lett. 2017 Mar 6;8(4):401-406. doi: 10.1021/acsmedchemlett.6b00488. eCollection 2017 Apr 13.
Ref 16	The progress of small-molecules and degraders against BCR-ABL for the treatment of CML. Eur J Med Chem. 2022 Aug 5;238:114442. doi: 10.1016/j.ejmech.2022.114442. Epub 2022 May 6.
Ref 17	Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. Bioorg Med Chem Lett. 2015 Sep 1;25(17):3458-63. doi: 10.1016/j.bmcl.2015.07.006. Epub 2015 Jul 9.
Ref 18	A pulse at the heart of targeted therapy. Nat Chem Biol. 2009 Mar;5(3):144-5. doi: 10.1038/nchembio0309-144.
Ref 19	SureChEMBL: a large-scale, chemically annotated patent document database. Nucleic Acids Res. 2016 Jan 4;44(D1):D1220-8. doi: 10.1093/nar/gkv1253. Epub 2015 Nov 17.
Ref 20	The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. doi: 10.1073/pnas.0702654104. Epub 2007 Aug 7.
Ref 21	PubChem BioAssay data set.
Ref 22	Prediction of Thorough QT study results using action potential simulations based on ion channel screens. J Pharmacol Toxicol Methods. 2014 Nov-Dec;70(3):246-54. doi: 10.1016/j.vascn.2014.07.002. Epub 2014 Jul 31.
Ref 23	Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors. Eur J Med Chem. 2016 Aug 25;119:70-82. doi: 10.1016/j.ejmech.2016.04.056. Epub 2016 Apr 25.
Ref 24	The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series. Eur J Med Chem. 2019 Feb 1;163:610-625. doi: 10.1016/j.ejmech.2018.12.012. Epub 2018 Dec 11.
Ref 25	From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer. J Med Chem. 2016 Nov 10;59(21):9788-9805. doi: 10.1021/acs.jmedchem.6b00943. Epub 2016 Oct 26.
Ref 26	Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents. Eur J Med Chem. 2015;96:269-80. doi: 10.1016/j.ejmech.2015.04.027. Epub 2015 Apr 13.
Ref 27	Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents. Eur J Med Chem. 2013 May;63:702-12. doi: 10.1016/j.ejmech.2013.03.013. Epub 2013 Mar 16.
Ref 28	Sesquiterpenoids from Bombax malabaricum. J Nat Prod. 2007 Sep;70(9):1526-8. doi: 10.1021/np070256j. Epub 2007 Sep 1.
Ref 29	Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives. Bioorg Med Chem Lett. 2012 Jan 15;22(2):806-10. doi: 10.1016/j.bmcl.2011.12.070. Epub 2011 Dec 20.
Ref 30	Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors. RSC Med Chem. 2020 May 19;11(6):665-675. doi: 10.1039/d0md00049c. eCollection 2020 Jun 1.
Ref 31	Development of a chimeric c-Src kinase and HDAC inhibitor. ACS Med Chem Lett. 2013 Aug 8;4(8):779-783. doi: 10.1021/ml400175d.
Ref 32	Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy. J Med Chem. 2022 Jan 27;65(2):955-982. doi: 10.1021/acs.jmedchem.1c00335. Epub 2021 Jun 3.
Ref 33	Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity. J Med Chem. 2022 Oct 27;65(20):13705-13713. doi: 10.1021/acs.jmedchem.2c00751. Epub 2022 Oct 7.
Ref 34	Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer. J Med Chem. 2015 May 14;58(9):3957-74. doi: 10.1021/acs.jmedchem.5b00270. Epub 2015 Apr 16.
Ref 35	Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration. J Med Chem. 2022 Jan 27;65(2):1313-1328. doi: 10.1021/acs.jmedchem.1c00440. Epub 2021 Aug 1.
Ref 36	Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity.
Ref 37	ARN25068, a versatile starting point towards triple GSK-3/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders. Eur J Med Chem. 2022 Feb 5;229:114054. doi: 10.1016/j.ejmech.2021.114054. Epub 2021 Dec 16.
Ref 38	Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. Eur J Med Chem. 2022 Jul 5;237:114346. doi: 10.1016/j.ejmech.2022.114346. Epub 2022 Apr 6.
Ref 39	Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation. J Med Chem. 2014 Aug 14;57(15):6834-44. doi: 10.1021/jm5009242. Epub 2014 Jul 30.
Ref 40	Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography. J Med Chem. 2013 Jan 10;56(1):84-96. doi: 10.1021/jm301187e. Epub 2012 Dec 19.
Ref 41	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections. J Med Chem. 2022 Jan 27;65(2):893-921. doi: 10.1021/acs.jmedchem.0c01467. Epub 2021 Feb 4.
Ref 42	Kinase Inhibitors as Underexplored Antiviral Agents. J Med Chem. 2022 Jan 27;65(2):935-954. doi: 10.1021/acs.jmedchem.1c00302. Epub 2021 May 10.
Ref 43	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. Eur J Med Chem. 2021 Jan 1;209:112904. doi: 10.1016/j.ejmech.2020.112904. Epub 2020 Oct 8.
Ref 44	Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors. ACS Med Chem Lett. 2015 Jun 4;6(7):798-803. doi: 10.1021/acsmedchemlett.5b00143. eCollection 2015 Jul 9.
Ref 45	Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma. Eur J Med Chem. 2019 Feb 1;163:671-689. doi: 10.1016/j.ejmech.2018.12.015. Epub 2018 Dec 7.
Ref 46	Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine. Eur J Med Chem. 2015 Nov 2;104:139-47. doi: 10.1016/j.ejmech.2015.09.034. Epub 2015 Oct 8.
Ref 47	Discovery of a potent p38/MAPK14 kinase inhibitor: Synthesis, in?vitro/in?vivo biological evaluation, and docking studies. Eur J Med Chem. 2019 Dec 1;183:111684. doi: 10.1016/j.ejmech.2019.111684. Epub 2019 Sep 8.
Ref 48	Colony stimulating factor-1 receptor as a target for small molecule inhibitors. Bioorg Med Chem. 2010 Mar 1;18(5):1789-97. doi: 10.1016/j.bmc.2010.01.056. Epub 2010 Jan 28.
Ref 49	Improved angiostatic activity of dasatinib by modulation with hydrophobic chains. ACS Med Chem Lett. 2015 Jan 30;6(3):313-7. doi: 10.1021/ml500496u. eCollection 2015 Mar 12.
Ref 50	Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II. Bioorg Med Chem. 2018 Aug 7;26(14):4014-4024. doi: 10.1016/j.bmc.2018.06.027. Epub 2018 Jun 20.
Ref 51	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia. Bioorg Med Chem Lett. 2015 Oct 1;25(19):4320-4. doi: 10.1016/j.bmcl.2015.07.065. Epub 2015 Jul 26.
Ref 52	Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay. Eur J Med Chem. 2013 Mar;61:41-8. doi: 10.1016/j.ejmech.2012.06.007. Epub 2012 Jun 12.
Ref 53	Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)isoleucine(315) mutant. J Med Chem. 2012 Nov 26;55(22):10033-46. doi: 10.1021/jm301188x. Epub 2012 Nov 1.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.

Payload Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)